Anteris Technologies Global Corp. (AVR) Deep Dive Video

Summary

A recapitalized, Medtronic-validated biomimetic TAVR challenger whose valuation hinges on a single pivotal trial proving DurAVR can out-hemodynamics—and outlast—the incumbents.

View AVR stock page · Read the AVR research report

Loading the video player…